Skadden, Arps, Slate, Meagher & Flom and Jones Day, together with Wilmer Cutler Pickering Hale and Dorr, are advising on Japanese pharmaceutical research company Astellas Pharma's $5.9 billion acquisition of U.S. drugmaker Iveric Bio.